Skip to main content
Erschienen in: Oral and Maxillofacial Surgery 3/2023

24.06.2022 | Original Article

Efficacy of fibrin-rich platelets and leukocytes (L-PRF) in tissue repair in surgical oral procedures in patients using zoledronic acid—case–control study

verfasst von: Guilherme Klein Parise, Brenda Nazareth Costa, Miriã Lima Nogueira, Laurindo Moacir Sassi, Juliana Lucena Schussel

Erschienen in: Oral and Maxillofacial Surgery | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Medication-related osteonecrosis of the jaws (MRONJ) is a complication that develops in patients who use or have used antiresorptive or antiangiogenic medications for the treatment of bone metabolic disease and bone metastases. Clinically, MRONJ is characterized by the appearance of an inflammation in soft tissues and exposure of necrotic bone tissue in mandible or maxilla, for a period of 8 weeks, in patients with no history of head and neck radiotherapy that were being or are being treated with antiresorptive and/or antiangiogenic agents. The fibrin-rich platelets and leukocytes (L-PRF) membrane has been used as an alternative for MRONJ prevention. The aim of this study was to evaluate the use of L-PRF in prevention and treatment of bone necrosis.

Material and Methods

The patients included had MRONJ diagnosis confirmed after clinical and radiographic examination and patients whose only therapeutic option was dental extraction.

Results

Twenty patients were included in the study and were divided in three groups. Two patients were removed from the study due to previous history of pentoxifylline and tocopherol use. The result of surgical treatment was successful in 57% in group 1 (control/MRONJ prevention), 100% in group 2 (MRONJ prevention), and 80% in group 3 (MRONJ treatment).

Conclusion

L-PRF is an autologous biomaterial that allows the release of growth factors for a prolonged time, resulting in a better healing, reducing the risk contamination, edema, and postoperative pain, being a great ally in the prevention and treatment of MRONJ because it returns to these patients, mainly quality of life, reducing pain, and recurrent infections commonly seen in the processes of bone necrosis of the jaws.
Literatur
1.
Zurück zum Zitat He L, Sun X, Liu Z, Qiu Y, Niu Y (2020) Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci 12(1):30CrossRefPubMedPubMedCentral He L, Sun X, Liu Z, Qiu Y, Niu Y (2020) Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci 12(1):30CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61(9):1115–1117CrossRefPubMed Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61(9):1115–1117CrossRefPubMed
3.
Zurück zum Zitat de Almeida Fernando, Barros Mourao C, Calasans-Maia MD, Del Fabbro M, Le Drapper Vieira F, de Mello Coutinho, Machado R, Capella R et al (2020) The use of platelet-rich fibrin in the management of medication-related osteonecrosis of the jaw: a case series. J Stomatol Oral Maxillofac Surg. 121(1):84–9CrossRef de Almeida Fernando, Barros Mourao C, Calasans-Maia MD, Del Fabbro M, Le Drapper Vieira F, de Mello Coutinho, Machado R, Capella R et al (2020) The use of platelet-rich fibrin in the management of medication-related osteonecrosis of the jaw: a case series. J Stomatol Oral Maxillofac Surg. 121(1):84–9CrossRef
4.
Zurück zum Zitat Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72(10):1938–1956CrossRefPubMed Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72(10):1938–1956CrossRefPubMed
5.
Zurück zum Zitat Maciel AP, Quispe RA, Martins LJO, Caldas RJ, Santos P (2020) Clinical profile of individuals with bisphosphonate-related osteonecrosis of the jaw: an integrative review. Sao Paulo Med J 138(4):326–335CrossRefPubMedPubMedCentral Maciel AP, Quispe RA, Martins LJO, Caldas RJ, Santos P (2020) Clinical profile of individuals with bisphosphonate-related osteonecrosis of the jaw: an integrative review. Sao Paulo Med J 138(4):326–335CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Rodan GA (1998) Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol San Diego 38:375–388CrossRef Rodan GA (1998) Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol San Diego 38:375–388CrossRef
7.
Zurück zum Zitat Steller D, Herbst N, Pries R, Juhl D, Hakim SG (2019) Positive impact of platelet-rich plasma and platelet-rich fibrin on viability, migration and proliferation of osteoblasts and fibroblasts treated with zoledronic acid. Sci Rep 9(1):8310CrossRefPubMedPubMedCentral Steller D, Herbst N, Pries R, Juhl D, Hakim SG (2019) Positive impact of platelet-rich plasma and platelet-rich fibrin on viability, migration and proliferation of osteoblasts and fibroblasts treated with zoledronic acid. Sci Rep 9(1):8310CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Hristamyan M, Raycheva R, Pechalova P, Hristamyan V, Stoilova Y (2021) Risk factors in patients with bisphosphonate - associated osteonecrosis of the jaws. Journal of IMAB - Annual Proceeding (Scientific Papers) 27(1):3543–3548CrossRef Hristamyan M, Raycheva R, Pechalova P, Hristamyan V, Stoilova Y (2021) Risk factors in patients with bisphosphonate - associated osteonecrosis of the jaws. Journal of IMAB - Annual Proceeding (Scientific Papers) 27(1):3543–3548CrossRef
9.
Zurück zum Zitat De Cassia Tornier S, Macedo FJ, Sassi LM, Schussel JL. (2021) Quality of life in cancer patients with or without medication-related osteonecrosis of the jaw. Supportive Care in Cancer, [s. l.], n. 0123456789. De Cassia Tornier S, Macedo FJ, Sassi LM, Schussel JL. (2021) Quality of life in cancer patients with or without medication-related osteonecrosis of the jaw. Supportive Care in Cancer, [s. l.], n. 0123456789.
10.
Zurück zum Zitat Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL et al (2019) Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol 37(25):2270–2290CrossRefPubMed Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL et al (2019) Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol 37(25):2270–2290CrossRefPubMed
11.
Zurück zum Zitat Yuce MO, Adali E, Isik G. (2021) The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clin Oral Investig. Yuce MO, Adali E, Isik G. (2021) The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study. Clin Oral Investig.
12.
Zurück zum Zitat Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P et al (2014) A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol 50(11):1049–1057CrossRefPubMed Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P et al (2014) A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol 50(11):1049–1057CrossRefPubMed
13.
Zurück zum Zitat Inchingolo F, Cantore S, Dipalma G, Georgakopoulos I, Almasri M, Gheno E, Motta A, Marrelli M, Farronato D, Ballini A, Marzullo A (2017) Platelet rich fibrin in the management of medication-related osteonecrosis of the jaw: a clinical and histopathological evaluation. J Biol Regul Homeost Agents. 31(3):811–816PubMed Inchingolo F, Cantore S, Dipalma G, Georgakopoulos I, Almasri M, Gheno E, Motta A, Marrelli M, Farronato D, Ballini A, Marzullo A (2017) Platelet rich fibrin in the management of medication-related osteonecrosis of the jaw: a clinical and histopathological evaluation. J Biol Regul Homeost Agents. 31(3):811–816PubMed
14.
Zurück zum Zitat Szentpeteri S, Schmidt L, Restar L, Csaki G, Szabo G, Vaszilko M (2020) The effect of platelet-rich fibrin membrane in surgical therapy of medication-related osteonecrosis of the jaw. J Oral Maxillofac Surg 78(5):738–748CrossRefPubMed Szentpeteri S, Schmidt L, Restar L, Csaki G, Szabo G, Vaszilko M (2020) The effect of platelet-rich fibrin membrane in surgical therapy of medication-related osteonecrosis of the jaw. J Oral Maxillofac Surg 78(5):738–748CrossRefPubMed
15.
Zurück zum Zitat Nica DF, Riviș M, Roi CI, Todea CD, Duma VF, Sinescu C (2021) Complementarity of photo-biomodulation, surgical treatment, and antibiotherapy for medication-related osteonecrosis of the jaws (MRONJ). Med 57(2):1–14 Nica DF, Riviș M, Roi CI, Todea CD, Duma VF, Sinescu C (2021) Complementarity of photo-biomodulation, surgical treatment, and antibiotherapy for medication-related osteonecrosis of the jaws (MRONJ). Med 57(2):1–14
16.
Zurück zum Zitat Bracher AI, Vig N, Burkhard J-P, Schaller B, Schlittler F (2021) The application of platelet rich fibrin in patients presenting with osteonecrosis of the jaw: a systematic literature review. Adv Oral Maxillofac Surg 2(March):100076CrossRef Bracher AI, Vig N, Burkhard J-P, Schaller B, Schlittler F (2021) The application of platelet rich fibrin in patients presenting with osteonecrosis of the jaw: a systematic literature review. Adv Oral Maxillofac Surg 2(March):100076CrossRef
17.
Zurück zum Zitat Kim JW, Kim SJ, Kim MR (2014) Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. Br J Oral Maxillofac Surg 52(9):854–859CrossRefPubMed Kim JW, Kim SJ, Kim MR (2014) Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. Br J Oral Maxillofac Surg 52(9):854–859CrossRefPubMed
18.
Zurück zum Zitat Curi MM, Cossolin GSI, Koga DH, Zardetto C, Christianini S, Feher O et al (2011) Bisphosphonate-related osteonecrosis of the jaws - an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg 69(9):2465–2472CrossRefPubMed Curi MM, Cossolin GSI, Koga DH, Zardetto C, Christianini S, Feher O et al (2011) Bisphosphonate-related osteonecrosis of the jaws - an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg 69(9):2465–2472CrossRefPubMed
19.
Zurück zum Zitat Park JH, Kim JW, Kim SJ (2017) Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw? J Oral Maxillofac Surg 75(6):1176–1184CrossRefPubMed Park JH, Kim JW, Kim SJ (2017) Does the addition of bone morphogenetic protein 2 to platelet-rich fibrin improve healing after treatment for medication-related osteonecrosis of the jaw? J Oral Maxillofac Surg 75(6):1176–1184CrossRefPubMed
20.
Zurück zum Zitat Maluf G, Caldas RJ, Silva Santos PS (2018) Use of leukocyte- and platelet-rich fibrin in the treatment of medication-related osteonecrosis of the jaws. J Oral Maxillofac Surg 76(1):88–96CrossRefPubMed Maluf G, Caldas RJ, Silva Santos PS (2018) Use of leukocyte- and platelet-rich fibrin in the treatment of medication-related osteonecrosis of the jaws. J Oral Maxillofac Surg 76(1):88–96CrossRefPubMed
21.
Zurück zum Zitat Michael E, Pooja G, Sneha S (2019) Mylohyoid flap and platelet rich fibrin in the treatment of medication related osteonecrosis of the jaws. Res Reports Oral Maxillofac Surg 3(1):5–8 Michael E, Pooja G, Sneha S (2019) Mylohyoid flap and platelet rich fibrin in the treatment of medication related osteonecrosis of the jaws. Res Reports Oral Maxillofac Surg 3(1):5–8
22.
Zurück zum Zitat Bennardo F, Buffone C, Muraca D, Antonelli A, Giudice A. (2020) Medication-related osteonecrosis of the jaw with spontaneous hemimaxilla exfoliation: report of a case in metastatic renal cancer patient under multidrug therapy. Case Rep Med. 2020. Bennardo F, Buffone C, Muraca D, Antonelli A, Giudice A. (2020) Medication-related osteonecrosis of the jaw with spontaneous hemimaxilla exfoliation: report of a case in metastatic renal cancer patient under multidrug therapy. Case Rep Med. 2020.
23.
Zurück zum Zitat Asaka T, Ohga N, Yamazaki Y, Sato J, Satoh C, Kitagawa Y (2017) Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study. Clin Oral Investig 21(7):2165–2172CrossRefPubMed Asaka T, Ohga N, Yamazaki Y, Sato J, Satoh C, Kitagawa Y (2017) Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study. Clin Oral Investig 21(7):2165–2172CrossRefPubMed
24.
Zurück zum Zitat Michalak F, Hnitecka S, Dominiak M, Grzech-Leśniak K (2021) Schemes for drug-induced treatment of osteonecrosis of jaws with particular emphasis on the influence of vitamin d on therapeutic effects. Pharmaceutics 13(3):1–13CrossRef Michalak F, Hnitecka S, Dominiak M, Grzech-Leśniak K (2021) Schemes for drug-induced treatment of osteonecrosis of jaws with particular emphasis on the influence of vitamin d on therapeutic effects. Pharmaceutics 13(3):1–13CrossRef
25.
Zurück zum Zitat Yanaguizawa WH, Velasco SK, Petersen RL, Alves FDA, Cavalcanti MGP. (2020) Imaging modalities in medication-related osteonecrosis of the jaw. Clin Lab Res Dent. 1–7. Yanaguizawa WH, Velasco SK, Petersen RL, Alves FDA, Cavalcanti MGP. (2020) Imaging modalities in medication-related osteonecrosis of the jaw. Clin Lab Res Dent. 1–7.
26.
Zurück zum Zitat On SW, Cho SW, Byun SH, Yang BE (2021) Various therapeutic methods for the treatment of medication-related osteonecrosis of the jaw (MRONJ) and their limitations: a narrative review on new molecular and cellular therapeutic approaches. Antioxidants. 10:5CrossRef On SW, Cho SW, Byun SH, Yang BE (2021) Various therapeutic methods for the treatment of medication-related osteonecrosis of the jaw (MRONJ) and their limitations: a narrative review on new molecular and cellular therapeutic approaches. Antioxidants. 10:5CrossRef
27.
Zurück zum Zitat Şahin O, Akan E, Tatar B, Ekmekcioğlu C, Ünal N, Odabaşı O. (2021) Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients. Braz J Otorhinolaryngol. (xx). Şahin O, Akan E, Tatar B, Ekmekcioğlu C, Ünal N, Odabaşı O. (2021) Combined approach to treatment of advanced stages of medication-related osteonecrosis of the jaw patients. Braz J Otorhinolaryngol. (xx).
28.
Zurück zum Zitat Law B, Soh HY, Nabil S, Rajandram RK, Nazimi AJ, Ramli R. Autologous platelet-rich fibrin (PRF) as an adjunct in the management of osteoradionecrosis and medication-related osteonecrosis of jaws. case series in a single centre. Appl Sci. 2021;11(8). Law B, Soh HY, Nabil S, Rajandram RK, Nazimi AJ, Ramli R. Autologous platelet-rich fibrin (PRF) as an adjunct in the management of osteoradionecrosis and medication-related osteonecrosis of jaws. case series in a single centre. Appl Sci. 2021;11(8).
29.
Zurück zum Zitat Miranda M, Gianfreda F, Raffone C, Antonacci D, Pistilli V, Bollero P. (2021) The role of platelet-rich fibrin (PRF) in the prevention of medication-related osteonecrosis of the jaw (MRONJ). Biomed Res Int. 2021. Miranda M, Gianfreda F, Raffone C, Antonacci D, Pistilli V, Bollero P. (2021) The role of platelet-rich fibrin (PRF) in the prevention of medication-related osteonecrosis of the jaw (MRONJ). Biomed Res Int. 2021.
30.
Zurück zum Zitat Fortunato L, Bennardo F, Buffone C, Giudice A (2020) Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review J Cranio-Maxillofacial Surg 48(3):268–285CrossRef Fortunato L, Bennardo F, Buffone C, Giudice A (2020) Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review J Cranio-Maxillofacial Surg 48(3):268–285CrossRef
31.
Zurück zum Zitat He L, Sun X, Liu Z, Qiu Y, Niu Y (2020) Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci 12(1):1–11CrossRef He L, Sun X, Liu Z, Qiu Y, Niu Y (2020) Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci 12(1):1–11CrossRef
32.
Zurück zum Zitat Feng M, Wang Y, Zhang P, Zhao Q, Yu S, Shen K et al (2020) Antibacterial effects of platelet-rich fibrin produced by horizontal centrifugation. Int J Oral Sci 12(1):1–8CrossRef Feng M, Wang Y, Zhang P, Zhao Q, Yu S, Shen K et al (2020) Antibacterial effects of platelet-rich fibrin produced by horizontal centrifugation. Int J Oral Sci 12(1):1–8CrossRef
Metadaten
Titel
Efficacy of fibrin-rich platelets and leukocytes (L-PRF) in tissue repair in surgical oral procedures in patients using zoledronic acid—case–control study
verfasst von
Guilherme Klein Parise
Brenda Nazareth Costa
Miriã Lima Nogueira
Laurindo Moacir Sassi
Juliana Lucena Schussel
Publikationsdatum
24.06.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Oral and Maxillofacial Surgery / Ausgabe 3/2023
Print ISSN: 1865-1550
Elektronische ISSN: 1865-1569
DOI
https://doi.org/10.1007/s10006-022-01094-7

Weitere Artikel der Ausgabe 3/2023

Oral and Maxillofacial Surgery 3/2023 Zur Ausgabe

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.